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Abstract: Candida auris is an emerging pathogen that needs to be controlled effectively due to its
association with a high mortality rate. The presence of biofilms on dry surfaces has been shown to
be widespread in healthcare settings. We produced a C. auris dry surface biofilm (DSB) on stainless
steel surfaces following sequential hydration and desiccation cycles for 12 days. The ASTM2967-15
was used to measure the reduction in viability of 12 commercially wipe-based disinfectants and
sodium hypochlorite (1000 ppm) against C. auris DSB. We also evaluated C. auris transferability
and biofilm regrowth post-treatment. A peracetic acid (3500 ppm) product and two chlorine-based
products (1000 ppm available chlorine) were successful in reducing C. auris viability and delaying
DSB regrowth. However, 50% of the products tested failed to decrease C. auris viability, 58% failed to
prevent its transferability, and 75% did not delay biofilm regrowth. Using three different parameters
to measure product efficacy provided a practical evaluation of product effectiveness against C. auris
DSB. Although log10 reduction in viability is traditionally measured, transferability is an important
factor to consider from an infection control and prevention point of view as it allows for determination
of whether the surface is safe to touch by patients and hospital staff post-treatment.
Keywords: Candida auris; dry-biofilm; disinfection; peracetic acid; sodium hypochlorite; chlorine
dioxide; sodium dichloroisocyanurate; transferability; regrowth
1. Introduction
Candida auris was first isolated and identified in Japan in 2009 [1]. C. auris is an emerging pathogen
responsible for many life-threating infections and it can be associated with high mortality rates [2].
C. auris infections are difficult to treat mostly due to the unpredictable resistance profile of the yeast
to anti-fungal agents, frequent misidentification, non-aggregative phenotype, and its ability to form
biofilm [3]. Higher risk of candidemia occurs in immunocompromised patients, patients that have
undergone antibiotic or anti-fungal therapy, patients after surgeries, and patients with central venous
catheters [4].
Contaminated surfaces in healthcare settings contribute to the transmission of infectious
diseases [5–7]. Vickery and colleagues [8] showed that pathogens embedded in dry surface biofilms
(DSB) remain on hospital surfaces despite rigorous surface decontamination. The widespread
presence of dry surface biofilms on healthcare surfaces has now been established [9,10]. C. auris
can persist on surfaces for weeks [11,12] and transmission of C. auris in healthcare settings have
been reported [2,4,13,14]. The elimination of C. auris from surfaces is therefore important to consider.
However, not many studies have investigated the effectiveness of disinfectants against C. auris [15].
Public Health England guidance [16] for the management and infection prevention and control of
C. auris recommends using hypochlorite at 1000 ppm available chlorine to terminally clean room or
bed space after the discharge of a C. auris infected or colonized patient. Not surprisingly, the majority
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of efficacy studies against C. auris relates to chlorine-releasing agents [14,17–19], although other
biocides have been considered, such as quaternary ammonium compounds [14,18], acetic acid [18],
peracetic acid [19], and hydrogen peroxide [17]. All these studies but one studied planktonic
(suspension of) C. auris [20]. None of these studies investigated the transferability of C. auris to
other surfaces post-treatment. Here, we investigated the efficacy of 12 commercially available products
and sodium hypochlorite 1000 ppm against C. auris DSB using a modified product efficacy test
protocol ASTM2967-15 [21] to measure decreases in viability, transferability, and biofilm regrowth
post-treatment. The evaluation of three different parameters provides a better and more practical
understanding of product efficacy against this pathogen.
2. Materials and Methods
C. auris Growth and Maintenance
C. auris (DSM 21092) was propagated overnight in malt extract broth (MEB, Oxoid, Thermo
Scientific™, Loughborough, UK) at 25 ◦C and the pellet was re-suspended in MEB following
centrifugation at 1200× g. The yeast suspension was adjusted to 1 × 106 CFU/mL.
C. auris Organic Load (OL) Dry-Biofilm Model
The C. auris DSB model is based on a recently developed Staphylococcus aureus DSB protocol [22].
Briefly, dry-biofilm formation consists of alternating hydration and desiccation phases in the presence
of an organic load (OL). Stainless steel AISI 430 discs (0.7 ± 0.07 mm thickness; 10 ± 0.5 mm diameter,
Goodfellow Cambridge Limited, Huntington, UK) were used as support. Sterile discs were placed
in wells of a Corning™ Costar™ flat-bottom cell culture plates (Fisher Scientific™, Loughborough,
UK), containing 1 mL of MEB with 5% anhydrous D-glucose (Fisher Scientific, Loughborough, UK),
3 g/L bovine serum albumin (BSA; Sigma® Life Science, Dorset, UK), and 106 CFU/mL washed
C. auris suspension. Yeasts were first allowed to attach and form a biofilm on the disc surface for
2 days at 25 ◦C under gentle agitation using an Orbit P4 plate rocker (Labnet International, Edison, NJ,
USA). The suspension was then drained from the wells, and plates were incubated at 25 ◦C for 48 h.
Following this dry phase, 1 mL of MEB with 3 g/L BSA was added to each well, and a new hydrated
phase began for 48 h. Hydrated and dry phases alternated every 48 h for a period of 12 days, ending
with biofilm in a dry phase.
Scanning Electron Microscopy (SEM) Imaging
C. auris DSB samples were prepared by overnight incubation of discs in a 2.5% glutaraldehyde
solution (ACROS Organics™, Fisher Scientific, Loughborough, UK) followed by immersion in
successive concentrations of 10%, 25%, 50%, 70%, 90%, and 100% ethanol (Honeywell, Fisher Scientific
Ltd., Loughborough, UK) for 10 min each. Prior to scanning electron microscopy (SEM, Carl Zeiss Ltd.,
Cambridge, UK) scanning, samples were coated with 20 nm of AuPd coating with a sputter coater
(SC500, Biorad, UK). Secondary electron images were acquired with a beam energy of 5 kV using an
in-lens detector on a Sigma HD Field Emission Gun Scanning Electron Microscope (Carl Zeiss Ltd.,
Cambridge, UK) at ×2000 and ×10,000 magnification and a 5 mm working distance. SEM images were
false-colored to help visualization and contrast using GNU Image manipulation program (GIMP 2.8)
software. Images were not otherwise altered.
Product Tested
The effectiveness of four commercially available wipes and eight commercially available liquid
disinfectants was tested against C. auris OL dry-biofilm (Table 1). Disinfectants were prepared
according to manufacturers’ instructions and combined with Rubbermaid® HYGEN™ disposable
microfiber cloth (Rubbermaid Products, Surrey, UK), allowing 2.5 mL of disinfectant per 1 g of wipe.
Wipes were cut into 3 × 3 cm2 squares prior to testing.
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Table 1. Disinfectants tested.
Abbreviation Main ActiveIngredient 1 Excipients (from MSDS)
1
Concentration of the
Main Active
Ingredient 4
pH 5 Mechanism of Disinfectant Action 6 Wipe Material
BZK
Benzalkonium
chloride,
polyhexamethylene
biguanide (PHMB)
Didecyl dimethyl ammonium
chloride < 0.5% (<5000 ppm) 5.41
Membrane active agents; damage cytoplasmic
membrane and increase permeability [23] Non-Woven Wipe
7
ClO2-1 Chlorine dioxide
Sodium chlorite, sodium dodecyl
sulphate, sodium carbonate,
citric acid, sodium
dichloroisocyanurate
300 ppm 5.05 Affect membrane permeability of the membrane
and inhibits cellular respiration [23]
Microfiber cloth 8
ClO2-2 Chlorine dioxide Not mentioned 1000 ppm 4.31 Microfiber cloth 8
NaDCC-1 Sodiumdichloroisocyanurate
Adipic acid, arylsulfonates,
sodium fatty acid sarcosides 1000 ppm 6.31
Permeabilization of the cytoplasmic
membrane [24], progressive oxidation of thiol
groups to disulphides [25] and deleterious effects
on DNA synthesis [26]
Microfiber cloth 8
NaDCC-2 Sodiumdichloroisocyanurate
Adipic acid, sodium toluene
sulphonate, sodium
n-lauroylsarcosinate
1000 ppm 5.93 Microfiber cloth 8
NaDCC-3 Sodiumdichloroisocyanurate Sulfonic acid 10,000 ppm 5.77 Non-woven wipe
9
NaDCC-4 Sodiumdichloroisocyanurate Adipic acid, sodium carbonate 1000 ppm 5.86 Microfiber cloth
8
NaDCC-5 Sodiumdichloroisocyanurate
Adipic acid, sodium
toluenesulphonate, sodium
N-lauroyl sarcosinate
1000 ppm 5.64 Microfiber cloth 8
NaOCl-Ref 2 Sodium hypochlorite N/A 1000 ppm 11.31
Biosynthetic alterations in cellular
metabolism [27], phospholipid degradation,
irreversible enzymatic inactivation in bacteria,
lipid and fatty acid degradation [28]
Microfiber cloth 8
NaOCl-2 Sodium hypochlorite Sodium hydroxide, sodiumchloride 500 ppm 8.68 Non-woven wipe
7
NaOCl-3 Sodium hypochlorite
phosphoric acid (trisodium salt,
dodecahydrate), sodium
hydroxide, phosphoric acid
1000 ppm 13.13 Non-woven wipe 7
PAA-1 Peracetic acid sodium percarbonate, citric acid 3500 ppm 8.82 Rupture or dislocation of cell wall, disruption of
biochemical processes intercellularly [29] and
impairment of DNA replication [30]
Non-woven wipe 9
PAA-2 Peracetic acid Not mentioned 250 ppm 7.74 Microfibre cloth 8
Water 3 N/A N/A N/A 6.99 N/A Microfibre cloth 8
1: Main active ingredient and excipients mentioned in the MSDS information of the commercial products used in this study. 2: Unformulated sodium hypochlorite (1000 ppm), used as
reference. 3: Sterile deionized water. 4: Concentration of available chlorine/peracetic acid concentration was measured with Pocket Colorimeter™ (HACH®, Manchester, UK) (regardless
of the product claim on label) via the N, N-diethyl-p-phenylenediamine (DPD) method. 5: pH was measured by bench top pH meter (HANNA® Instruments, Leighton Buzzard,
UK). 6: Reported mechanisms of action, mainly from studies of bacteria. 7: Wipe originally moisturized with disinfectant by the manufacturer. 8: Disinfectant prepared according to
manufacturer’s instruction and then placed on Rubbermaid® HYGEN™ disposable microfiber cloth (2.5 mL of liquid per 1 g of cloth). 9: Dry non-woven wipe impregnated with powder
particles—needs to be wetted according to manufacturer instructions prior to use.
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ASTM E2967-15 Test
Disinfection tests were performed according to a modified ASTM E2967-15 test [21]. Briefly,
DSB were wiped with the Wiperator (Filtaflex Ltd., Almonte, Ontario, Canada) from both sides for 10 s
under 500 g pressure, left for 2 min at 25 ◦C, and then neutralized in Dey-Engley neutralizing (DE)
broth (Neogen® Corporation, Ayr, UK). Transfer of viable yeasts from used wipes to clean sterile disc
was not performed.
Reduction in Viability for Yeasts Embedded in Dry Biofilms
Following wiping, samples were incubated for 1 h at 25 ◦C in 2 mL DE with 100 µg/mL proteinase
K (Fisher Bioreagents™, Fisher Scientific, Loughborough, UK) and 1 g of glass beads (Fisher Scientific,
Loughborough, UK). After incubation, samples were vortexed for 2 min and then serially diluted,
and 3 × 10 µL2 drops of each dilution was plated onto tryptone soya agar (TSA; Oxoid, Thermo Fisher
Scientific, Newport, UK). Reduction in yeast viability, expressed as a log10 reduction, was calculated as
the difference between the number of yeasts recovered from untreated (control) and treated samples.
Transferability Test
Following wiping, discs were pressed 36 separate times with 100 g pressure on the surface of
DE agar. Following the transfer test, DE agar was incubated at 25 ◦C for a up to 5 days until colonies
appeared. Positive growth/adpression was recorded, and transferability was calculated as the number
of positive contact/number of adpressions.
Dry-Biofilm Regrowth
Following wiping, discs were placed in 30 mL capacity flat bottom glass bottle with 2 mL of DE
broth. The number of days for turbidity change, which is indicative of growth, was recorded. Samples
were plated on TSA to confirm yeast growth and purity.
Statistical Analysis
The statistical significance of data sets was evaluated with GraphPad PRISM® (version 7.04,
GraphPad Software, San Diego, CA, USA) using two- and one-way Analysis of Variance (ANOVA).
All experiments were performed in triplicates in three independent biological replicates unless
otherwise stated. The sample standard deviation was evaluated with Bassel’s correction.
3. Results
SEM Analysis of C. auris Dry Surface Biofilm
C. auris formed a thin biofilm that was evenly scattered throughout the stainless-steel disc surface
with no evidence of extracellular polymeric substances (Figure 1). There was no statistically significant
difference (two-way ANOVA, p = 0.06) in viable count of yeasts (log10 CFU/mL = 7.8 ± 0.3) recovered
from each disc between four independent biofilm batches.
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Product Efficacy
The most effective treatments including PAA-1 (3500 ppm), NaDCC-5 (1000 ppm), NaOCl-Ref
(1000 ppm), and NaOCl-3 (1000 ppm) removed or killed more than 7 log10 of C. auris embedded
in DSB (Figure 2). Peracetic acid at 3500 ppm combined with a non-woven wipe was significantly
(one-way ANOVA, p < 0.05) more effective in biofilm eradication than PAA at 250 ppm combined with
a microfiber cloth (0.84 ± 0.11 log10 reduction). NaDCC-5 was the most effective (two-way ANOVA,
p < 0.05) in killing or removing C. auris DSB compared to the other NaDCC-based products that all
failed to produce a 4 log10 reduction in viability (Figure 2). Chlorine-dioxide-based products overall
did not perform very well, achieving less than 2.5 log10 reduction even with ClO2-2 containing a higher
concentration (1000 ppm) of available chlorine (Figure 2). There was no difference (one-way ANOVA,
p = 0.22) in activity between ClO2-1 and ClO2-2. Overall, half of the products tested (ClO2-1, NaDCC-2,
and NaOCl-2) showed either a similar performance (one-way ANOVA, p > 0.05) to water combined
with the microfiber cloth or performed worse (one-way ANOVA, p < 0.05) than water combined with
the microfiber cloth (ClO2-2, NaDCC-3, and PAA-2).
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The best commercial products, NaDCC-3, NaDCC-5, and PAA-1, delayed the recovery of biofilm
post-treatment for more than 4 days (5.0 ± 0.0, 4.7 ± 1.2 and 6.5 ± 2.1 days, respectively; Figure 4).
Such activity was similar (two-way ANOVA, p = 0.53) to NaOCl-Ref which delayed regrowth by
4.5 ± 0.7 days. Nine out of 12 commercial treatments failed to prevent the regrowth of C. auris DSB for
more than 2 days (Figure 4).
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The less-reactive chemistry (as compared to the oxidizing chemistries) based on a quaternary
ammonium compound produced a 4 log10 reduction in C. auris on surfaces and reduced transferability
post-wiping to 20%.
4. Discussion
Environmental surfaces play an important role in the transmission of infection [5,6]. Infection
control regimens include the combination of cleaning and disinfection processes [16] and are often
based on the use of a disinfectant or cleaner combined with diverse materials [31]. Performance of
biocidal products still relies, however, on testing the efficacy of the formulation and not the combination
of formulation and material [22]. A number of US-based protocols to test wipe activity have been
described, but all had severe limitations in their setting or performance [31]. Recently, the ASTM2967-15
and the EN16615-15 protocols [32] have been recommended for evaluating the efficacy of antimicrobial
wipes, although EN16615-15 has recently been shown to lack stringency [33]. Both tests evaluate
the reduction in microbial number from the test surface and the transfer of micro-organisms during
wiping. Attaining a > 5log10 reduction in microbial inoculum following treatment has been, until now,
deemed to provide enough assurance that all micro-organisms would be killed on surfaces in practice.
Although this might be the case where surfaces are contaminated with a low number of microorganisms,
this might not be correct with surfaces contaminated with a high number of microorganisms or when
dry surface biofilms are present. Hence, the evaluation of microbial transferability post-treatment
is important to take into consideration to provide reassurance that a surface would be safe to touch.
The presence of DSB on healthcare surfaces has been established [8–10], and the resilience of DSB
to disinfection has been described [8]. The presence of C. auris DSB has not been yet established in
healthcare settings, although its persistence in healthcare settings has been described [11,12].
Here, we have successfully produced reproducible dry surface biofilms of C. auris on stainless steel
surfaces, for which appearance and characteristics are not dissimilar to artificial DSB of Staphylococcus
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aureus (Ledwoch, Said and Maillard, unpublished results) or DSB isolated from endoscopes [34].
These dry surface biofilms of C. auris provided a platform for testing the efficacy of commercially
available wipe-based products or formulation combined with a microfiber cloth. Here, we observed
that the majority of commercially available chlorine-releasing agents widely used by hospitals do
not effectively eradicate a C. auris DSB or lower its transferability. The ability of C. auris to form dry
surface biofilm on surfaces contribute somewhat to its resistance against disinfection. We showed
that C. auris inactivation was product dependent. NaOCl-containing products are widely used in
healthcare settings, although the efficacy of NaOCl against C. auris dried on surfaces differs in the
literature. While only 2.5–3 log10 of C. auris were killed by NaOCl (1000 ppm) within 5 min [20],
a 3000 ppm NaOCl solution resulted in reducing C. auris dried on surfaces for 2 h by 6 log10 in
1 min [18]. An 8000 ppm NaOCl solution, however, produced a 6 log10 reduction in 10 min for C. auris
dried on surfaces for 1 h [14]. Here, NaOCl-Ref (1000 ppm) and NaOCl-3 (1000 ppm) produced a
7 log10 reduction in number within 2 min following wiping.
The microfiber cloth loaded with sterile water enabled the removal of C. auris (2 log10 reduction)
but failed to prevent transfer or biofilm re-growth post wiping. Interestingly, a number of products
performed similarly to water, indicating either that the combination with the Rubbermaid® HYGEN™
disposable microfiber cloth was incompatible with the product formulation, or that the product activity
was caused by the material only. Wesgate et al. [33] recently showed that the type of material might
have a small impact on the formulation presumably because the concentration of the active ingredient
was high. In this study, it was interesting to observe that lower concentration and, possibly, the type of
material affected the efficacy of peracetic acid and NaOCl. It has also been reported that the formulation
itself impacts activity [35]. Here, different NaOCl formulations produced different results. While the
use of unformulated NaOCl (NaOCl-Ref) was effective in reducing counts of C. auris on surfaces and
prolonged biofilm regrowth, it failed to prevent C. auris transfer. The formulated NaOCl product
(NaOCl-3) containing the same concentration of available chlorine produced a high reduction in count,
thus preventing transfer but was less efficacious in delaying biofilm regrowth. NaOCl-2 containing
a lower concentration of available chlorine was not effective in reducing C. auris count, preventing
transfer, or delaying regrowth. The impact of formulation is also evident with NaDCC-based products.
Overall, the peracetic acid wipe product containing 3500 ppm of PAA performed the best against
C. auris DSB.
5. Conclusions
We successfully developed a dry surface biofilm in vitro model of C. auris. Although C. auris
has not yet been isolated from environmental DSB, its presence on surfaces and associated high
pathogenicity highlights the need to select an efficient infection control regimen. The use of
a product efficacy test such as ASTM2967-15 is essential to evaluate the efficacy of formulated
products. The additional evaluation of transferability of microorganisms post-wiping provides
important information on a product’s overall efficacy as well as reassurance that surfaces are safe
to touch post-treatment. Here, we observed that measuring log10 reduction in viability was not
enough to discriminate between product efficacy. Importantly, we observed that a number of
commercially-available formulations combined with a microfiber cloth, or products, failed to control
dry surface biofilms of C. auris. It was also clear that high concentration and an appropriate formulation
of the active ingredient was key for efficacy, with the PAA-based product performing better.
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